On this page
Dexamethasone Sodium Phosphate
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 084282-001 | DEXAMETHASONE SODIUM PHOSPHATE | INJECTABLE | DEXAMETHASONE SODIUM PHOSPHATE | Prescription | AP |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated (parenteral aqueous solutions)
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 59 | Labeling | Approved | June 5, 2024 | Standard |
| Supplement | 48 | Labeling | Approved | July 29, 2020 | Standard |
| Supplement | 46 | Labeling | Approved | October 25, 2016 | Standard |
| Supplement | 44 | Manufacturing (CMC) | Approved | July 11, 2000 | — |
| Supplement | 43 | Manufacturing (CMC) | Approved | September 7, 1999 | — |
| Supplement | 42 | Manufacturing (CMC) | Approved | December 1, 1998 | — |
| Supplement | 37 | Manufacturing (CMC) | Approved | June 16, 1998 | — |
| Supplement | 39 | Manufacturing (CMC) | Approved | June 12, 1998 | — |
| Supplement | 38 | Manufacturing (CMC) | Approved | May 7, 1998 | — |
| Supplement | 35 | Labeling | Approved | February 15, 1995 | — |
| Supplement | 36 | Manufacturing (CMC) | Approved | January 5, 1995 | — |
| Supplement | 34 | Labeling | Approved | January 27, 1994 | — |
| Supplement | 33 | Manufacturing (CMC) | Approved | August 28, 1992 | — |
| Supplement | 32 | Labeling | Approved | December 31, 1991 | — |
| Supplement | 31 | Labeling | Approved | October 28, 1991 | — |
| Supplement | 29 | Labeling | Approved | June 12, 1991 | — |
| Supplement | 27 | Manufacturing (CMC) | Approved | June 12, 1991 | — |
| Supplement | 28 | Manufacturing (CMC) | Approved | October 5, 1989 | — |
| Supplement | 26 | Labeling | Approved | March 15, 1989 | — |
| Supplement | 25 | Labeling | Approved | February 17, 1989 | — |
| Supplement | 24 | Labeling | Approved | September 7, 1988 | — |
| Supplement | 19 | Manufacturing (CMC) | Approved | January 11, 1988 | — |
| Supplement | 18 | Manufacturing (CMC) | Approved | January 11, 1988 | — |
| Supplement | 17 | Manufacturing (CMC) | Approved | January 11, 1988 | — |
| Supplement | 21 | Manufacturing (CMC) | Approved | October 22, 1985 | — |
| Supplement | 16 | Manufacturing (CMC) | Approved | December 7, 1984 | — |
| Supplement | 15 | Manufacturing (CMC) | Approved | February 17, 1983 | — |
| Supplement | 14 | Manufacturing (CMC) | Approved | February 17, 1983 | — |
| Original application | 1 | Approved | July 15, 1975 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20250109). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS A. Intravenous or intramuscular administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen diseases . During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic diseases. Pemphigus. Severe erythema multiforme (Stevens-Johnson Syndrome). Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Allergic corneal marginal ulcers. Keratitis. 7. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory diseases. Symptomatic Sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic disorders. Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults. Acute leukemic of childhood. 11. Edematous states. To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Nervous system. Acute exacerbations of multiple sclerosis. 13. Miscellaneous. Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy. Trichinosis with neurologic or myocardial in …
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION A. Intravenous or intramuscular administration The initial dosage of Dexamethasone sodium phosphate injection, USP may vary from 0.50 mg/day to 9.0 mg/day depending on the specific disease entity being treated. In situations of less severity, lower doses will generally suffice while in selected patients higher initial doses may be required. Usually the parenteral dosage ranges are one-third to one-half the oral dose given every 12 hours. However, in certain overwhelming, acute, life-threatening situations, administration of dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. For the treatment of unresponsive shock high pharmacologic doses of this product are currently recommended. Reported regimens range from 1 to 6 mg/kg of body weight as a single intravenous injection to 40 mg initially followed by repeat intravenous injection every 2 to 6 hours while shock persists. For the treatment of cerebral edema in adults an initial intravenous dose of 10 mg is recommended followed by 4 mg intramuscularly every six hours until maximum response has been noted. This regimen may be continued for several days postoperatively in patients requiring brain surgery. Oral dexamethasone, 1 to 3 mg t.i.d., should be given as soon as possible and dosage tapered off over a period of five to seven days. Nonoperative cases may require continuous therapy to remain free of symptoms of increased intracranial pressure. The smallest effective dose should be used in children, preferably orally. This may approximate 0.2 mg/kg/24 hours in divided doses. In treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day or 4–8 mg dexamethasone every other day for 1 month have been shown to be effective. The initial dosage should be maintained or adjusted until a satisfactory response is noted. If after a reasonable period of time there is a lack of satisfactory clinical response, Dexamethasone sodium phosphate injection, USP should be discontinued and the patient transferred to other appropriate therapy. It should be emphasized that dosage requirements are variable and must be individualized on the basis of the disease under treatment and the response of the patient. After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached. It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient's individual drug responsiveness and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment. In this later situation it may be necessary to increase the dosage of Dexamethasone sodium phosphate injection, USP for a period of time consistent with the patient's condition. If after a long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. B. Intra-articular, soft tissue or intralesional administration The dose for instrasynovial administration is usually 2 to 4 mg for large joints and 0.8 to 1 mg for small joints. For soft tissue and bursal injections a dose of 2 to 4 mg is recommended. Ganglia require a dose of 1 to 2 mg. A dose of 0.4 to 1 mg is used for injection into tendon sheaths. Injection into intervertebral joints should not be attempted at any time and hip joint injection cannot be recommended as an office procedure. Intrasynovial and soft tissue injections should be employed only when affected areas are limited to 1 or 2 sites. It should be remembered that corticoids provide palliation only and that other conve …
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Systemic fungal infections.
Warnings and Cautions
openFDA Drug LabelingSerious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. In patients on corticosteroid therapy subject to any unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Corticosteroids may mask some signs of infection, and new infections may appear during their use. There may be decreased resistance and inability to localize infection when corticosteroids are used. Prolonged use of corticosteroids may produce posterior subcapsular cataracts, glaucoma with possible damage to the optic nerves, and may enhance the establishment of secondary ocular infections due to fungi or viruses. Children who are on immunosuppressant drugs are more susceptible to infections than healthy children. Chickenpox and measles, for example, can have a more serious or even fatal course in children on immunosuppressant corticosteroids. In such children or in adults who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chickenpox develops, treatment with antiviral agents may be considered. Similarly, corticosteroids should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia. Usage in Pregnancy Since adequate human reproduction studies have not been done with corticosteroids, use of these drugs in pregnancy or in women of childbearing potential requires that the anticipated benefits be weighed against the possible hazards to the mother and embryo or fetus. Infants born of mothers who have received substantial doses of corticosteroids during pregnancy should be carefully observed for signs of hypoadrenalism. Average and large doses of cortisone or hydrocortisone can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Patients with a stressed myocardium should be observed carefully and the drug administered slowly since premature ventricular contractions may occur with rapid administration. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. While on corticosteroid therapy patients should not be vaccinated against smallpox. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially in high doses, because of possible hazards of neurological complications and lack of antibody response. The use of dexamethasone sodium phosphate injection in active tuberculosis should be restricted to those cases of fulminating or disseminated tuberculosis in which the corticosteroid is used for the management of the disease in conjunction with an appropriate anti-tuberculosis regimen. If corticosteroids are indicated in patients with latent tuberculosis or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. Because rare instances of anaphylactoid reactions have o …
Warnings
openFDA Drug LabelingWARNINGS Serious Neurologic Adverse Reactions with Epidural Administration Serious neurologic events, some resulting in death, have been reported with epidural injection of corticosteroids. Specific events reported include, but are not limited to, spinal cord infarction, paraplegia, quadriplegia, cortical blindness, and stroke. These serious neurologic events have been reported with and without use of fluoroscopy. The safety and effectiveness of epidural administration of corticosteroids have not been established, and corticosteroids are not approved for this use. In patients on corticosteroid therapy subject to any unusual stress, increased dosage of rapidly acting corticosteroids before, during and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including Dexamethasone Sodium Phosphate, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: • Reduce resistance to new infections • Exacerbate existing infections • Increase the risk of disseminated infections • Increase the risk of reactivation or exacerbation of latent infections • Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal. The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider Dexamethasone Sodium Phosphate withdrawal or dosage reduction as needed. Tuberculosis If Dexamethasone Sodium Phosphate is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, tuberculosis may occur. Closely monitor such patients for reactivation. During prolonged therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including Dexamethasone Sodium Phosphate. In corticosteroid-treated patients who have not had these diseases or are non- immune, particular care should be taken to avoid exposure to varicella and measles: • If a Dexamethasone Sodium Phosphate -treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. • If a Dexamethasone Sodium Phosphate -treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including Dexamethasone Sodium Phosphate. Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with Dexamethasone Sodium Phosphate. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy. Fungal Infections Corticosteroids, including Dexamethasone Sodium Phosphate, may exacerbate systemic fungal infections; therefore, avoid Dexamethasone Sodium Phosphate use in the presence of such infections unless Dexamethasone Sodium Phosphate is needed to control drug reactions. For patients on chronic Dexamethasone Sodium Phosphate therapy who develop systemic fungal infections, Dexamethasone Sodium Phosphate withdrawal or dosage reduction is recommended. Amebiasis Corticosteroids, including Dexamethasone Sodium Phosphate, may activate latent amebiasis. Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating Dexamethasone Sodium Phosphate in patients …
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at 1-800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. Fluid and electrolyte disturbances: Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal: Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal: Peptic ulcer with possible subsequent perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatological: Impaired wound healing Thin fragile skin Facial erythema Increased sweating May suppress reactions to skin tests Petechiae and ecchymoses Neurological: Convulsions Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Vertigo Headache Ophthalmic: Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Endocrine: Menstrual irregularities Development of cushingoid state Suppression of growth in children Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery, or illness Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Metabolic: Negative nitrogen balance due to protein catabolism Miscellaneous: Hyperpigmentation or hypopigmentation Subcutaneous and cutaneous atrophy Sterile abscess Post-injection flare, following intra-articular use Charcot-like arthropathy Itching, burning, tingling in the ano-genital region
Mechanism of Action
openFDA Drug LabelingACTIONS Naturally occurring glucocorticoids (hydrocortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Their synthetic analogs are primarily used for their potent anti-inflammatory effects in disorders of many organ systems. Glucocorticoids cause profound and varied metabolic effects. In addition, they modify the body’s immune responses to diverse stimuli.
Description
openFDA Drug LabelingDESCRIPTION Dexamethasone sodium phosphate injection, USP is a water-soluble inorganic ester of dexamethasone which produces a rapid response even when injected intramuscularly. Dexamethasone sodium phosphate, a synthetic adrenocortical steroid, is a white or slightly yellow crystalline powder. It is freely soluble in water and is exceedingly hygroscopic. The molecular weight is 516.41. It is designated chemically as 9-fluoro-11β,17-dihydroxy-16α-methyl-21-(phosphonooxy)pregna-1,4-diene-3, 20-dione disodium salt. The molecular formula is: C 22 H 28 FNa 2 O 8 P and the structural formula is: Dexamethasone Sodium Phosphate Injection is a sterile solution of dexamethasone sodium phosphate for intravenous and intramuscular use. The 4 mg/mL strength may also be used for intra-articular, intralesional and soft tissue administration. Each mL of Dexamethasone Sodium Phosphate Injection 4 mg/mL contains dexamethasone sodium phosphate, equivalent to 4 mg dexamethasone phosphate or 3.33 mg dexamethasone. Inactive ingredients per mL: 1 mg sodium sulfite anhydrous, 19.4 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection. Each mL of Dexamethasone Sodium Phosphate Injection 10 mg/mL contains dexamethasone sodium phosphate, equivalent to 10 mg dexamethasone phosphate or 8.33 mg dexamethasone. Inactive ingredients per mL: 1.5 mg sodium sulfite anhydrous, 16.5 mg sodium citrate anhydrous and 10.42 mg (0.01 mL) benzyl alcohol (preservative) in Water for Injection. The pH of both concentrations is 7.0-8.5; sodium hydroxide and/or citric acid used, if needed, for pH adjustment. Sealed under nitrogen. Structural formula
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP is supplied in the following dosage forms. NDC 51662-1297-1 DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP 20mg/5mL (4mg/mL) VIAL NDC 51662-1297-2 Pouch containing a single DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP 20mg/5mL (4mg/mL) VIAL NDC 51662-1297-3 Case of 25 Pouches - DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP 20mg/5mL (4mg/mL) VIAL HF Acquisition Co LLC, DBA HealthFirst Mukilteo, WA 98275 Also supplied in the following manufacture supplied dosage forms Dexamethasone Sodium Phosphate Injection, USP is available in the following package: 4 mg/mL 1 mL vials packaged in 25s (NDC 0641-6145-25) 5 mL vials packaged in 25s (NDC 0641-6146-25) 10 mg/mL 1 mL vials packaged in 25s (NDC 0641-0367-25) Storage Protect from light: Keep covered in carton until time of use. Store at 20°-25°C (68°-77°F), excursions permitted to 15°-30°C (59°-86°F) [See USP Controlled Room Temperature]. Avoid freezing. Do not use if solution is hazy or has a precipitate. Do not autoclave. To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-877-845-0689, or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. For Product Inquiry call 1-877-845-0689. Manufactured by: WEST-WARD A HIKMA COMPANY Eatontown, NJ 07724 USA Revised November 2016 462-331-05
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: DEXAMETHASONE SODIUM PHOSPHATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Recalls
Source: FDA Enforcement| Classification | Reported | Firm | Reason | Status |
|---|---|---|---|---|
| Class III | November 29, 2017 | West-Ward Pharmaceuticals Corp. | Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound). | Terminated |
| Class III | November 29, 2017 | West-Ward Pharmaceuticals Corp. | Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound). | Terminated |
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 50090-3541-0 | 50090-3541 | A-S Medication Solutions | 25 VIAL in 1 CARTON (50090-3541-0) / 1 mL in 1 VIAL | August 16, 2018 |
| 87063-289-10 | 87063-289 | ASCLEMED USA INC. | 10 VIAL in 1 CARTON (87063-289-10) / 5 mL in 1 VIAL (87063-289-01) | August 7, 2026 |
| 87063-289-25 | 87063-289 | ASCLEMED USA INC. | 25 VIAL in 1 CARTON (87063-289-25) / 5 mL in 1 VIAL (87063-289-01) | August 7, 2026 |
| 87063-290-25 | 87063-290 | ASCLEMED USA INC. | 25 VIAL in 1 CARTON (87063-290-25) / 1 mL in 1 VIAL (87063-290-01) | August 7, 2026 |
| 80425-0261-1 | 80425-0261 | Advanced Rx Pharmacy of Tennessee, LLC | 25 VIAL in 1 CARTON (80425-0261-1) / 1 mL in 1 VIAL | February 16, 2023 |
| 76420-555-01 | 76420-555 | Asclemed USA, Inc. | 1 mL in 1 VIAL (76420-555-01) | April 4, 2023 |
| 55154-5118-5 | 55154-5118 | Cardinal Health 107, LLC | 5 VIAL in 1 BAG (55154-5118-5) / 1 mL in 1 VIAL | September 7, 1982 |
| 72572-120-25 | 72572-120 | Civica, Inc. | 25 VIAL in 1 CARTON (72572-120-25) / 1 mL in 1 VIAL (72572-120-01) | November 13, 2019 |
| 72572-122-25 | 72572-122 | Civica, Inc. | 25 VIAL in 1 CARTON (72572-122-25) / 1 mL in 1 VIAL (72572-122-01) | November 13, 2019 |
| 55150-304-25 | 55150-304 | Eugia US LLC | 25 VIAL in 1 CARTON (55150-304-25) / 1 mL in 1 VIAL (55150-304-01) | June 5, 2020 |
| 55150-305-10 | 55150-305 | Eugia US LLC | 10 VIAL in 1 CARTON (55150-305-10) / 10 mL in 1 VIAL (55150-305-01) | June 7, 2019 |
| 68083-473-25 | 68083-473 | Gland Pharma Limited | 25 VIAL, SINGLE-DOSE in 1 CARTON (68083-473-25) / 1 mL in 1 VIAL, SINGLE-DOSE (68083-473-01) | August 4, 2021 |
| 68083-474-25 | 68083-474 | Gland Pharma Limited | 25 VIAL, MULTI-DOSE in 1 CARTON (68083-474-25) / 5 mL in 1 VIAL, MULTI-DOSE (68083-474-01) | August 4, 2021 |
| 68083-607-25 | 68083-607 | Gland Pharma Limited | 25 VIAL, SINGLE-DOSE in 1 CARTON (68083-607-25) / 1 mL in 1 VIAL, SINGLE-DOSE (68083-607-01) | September 25, 2023 |
| 51662-1297-1 | 51662-1297 | HF Acquisition Co LLC, DBA HealthFirst | 5 mL in 1 VIAL (51662-1297-1) | July 21, 2019 |
| 51662-1297-3 | 51662-1297 | HF Acquisition Co LLC, DBA HealthFirst | 25 POUCH in 1 CASE (51662-1297-3) / 1 mL in 1 POUCH (51662-1297-2) | January 11, 2021 |
| 51662-1343-3 | 51662-1343 | HF Acquisition Co LLC, DBA HealthFirst | 25 POUCH in 1 CASE (51662-1343-3) / 1 VIAL in 1 POUCH (51662-1343-2) / 1 mL in 1 VIAL (51662-1343-1) | December 22, 2018 |
| 51662-1541-3 | 51662-1541 | HF Acquisition Co LLC, DBA HealthFirst | 10 POUCH in 1 CASE (51662-1541-3) / 1 VIAL in 1 POUCH (51662-1541-2) / 10 mL in 1 VIAL (51662-1541-1) | May 20, 2022 |
| 51662-1660-3 | 51662-1660 | HF Acquisition Co LLC, DBA HealthFirst | 10 POUCH in 1 CASE (51662-1660-3) / 1 VIAL in 1 POUCH (51662-1660-2) / 5 mL in 1 VIAL (51662-1660-1) | July 15, 1975 |
| 0404-9805-05 | 0404-9805 | Henry Schein, Inc. | 1 VIAL in 1 BAG (0404-9805-05) / 5 mL in 1 VIAL | December 9, 2024 |
| 0641-0367-25 | 0641-0367 | Hikma Pharmaceuticals USA Inc. | 25 VIAL in 1 CARTON (0641-0367-25) / 1 mL in 1 VIAL (0641-0367-21) | September 7, 1982 |
| 0641-6145-25 | 0641-6145 | Hikma Pharmaceuticals USA Inc. | 25 VIAL in 1 CARTON (0641-6145-25) / 1 mL in 1 VIAL (0641-6145-01) | July 15, 1975 |
| 0641-6146-10 | 0641-6146 | Hikma Pharmaceuticals USA Inc. | 10 VIAL in 1 CARTON (0641-6146-10) / 5 mL in 1 VIAL (0641-6146-01) | October 3, 2023 |
| 0641-6146-25 | 0641-6146 | Hikma Pharmaceuticals USA Inc. | 25 VIAL in 1 CARTON (0641-6146-25) / 5 mL in 1 VIAL (0641-6146-01) | July 15, 1975 |
| 71872-7091-1 | 71872-7091 | Medical Purchasing Solutions, LLC | 1 VIAL in 1 BAG (71872-7091-1) / 1 mL in 1 VIAL | March 30, 2018 |
| 71872-7164-1 | 71872-7164 | Medical Purchasing Solutions, LLC | 1 VIAL in 1 BAG (71872-7164-1) / 1 mL in 1 VIAL | May 6, 2019 |
| 71872-7171-1 | 71872-7171 | Medical Purchasing Solutions, LLC | 1 VIAL in 1 BAG (71872-7171-1) / 1 mL in 1 VIAL | June 27, 2019 |
| 71872-7239-1 | 71872-7239 | Medical Purchasing Solutions, LLC | 1 VIAL in 1 BAG (71872-7239-1) / 10 mL in 1 VIAL | February 15, 2021 |
| 70518-0532-1 | 70518-0532 | REMEDYREPACK INC. | 25 VIAL in 1 CARTON (70518-0532-1) / 1 mL in 1 VIAL (70518-0532-0) | May 17, 2017 |
| 70518-3724-0 | 70518-3724 | REMEDYREPACK INC. | 25 VIAL in 1 CARTON (70518-3724-0) / 1 mL in 1 VIAL (70518-3724-1) | April 25, 2023 |
| 70069-021-25 | 70069-021 | Somerset Therapeutics, LLC | 25 VIAL in 1 CARTON (70069-021-25) / 1 mL in 1 VIAL (70069-021-01) | April 19, 2018 |
| 70069-022-25 | 70069-022 | Somerset Therapeutics, LLC | 25 VIAL, SINGLE-DOSE in 1 CARTON (70069-022-25) / 1 mL in 1 VIAL, SINGLE-DOSE (70069-022-01) | June 8, 2018 |
| 70069-023-25 | 70069-023 | Somerset Therapeutics, LLC | 25 VIAL, MULTI-DOSE in 1 CARTON (70069-023-25) / 5 mL in 1 VIAL, MULTI-DOSE (70069-023-01) | June 8, 2018 |
| 70069-024-25 | 70069-024 | Somerset Therapeutics, LLC | 25 VIAL, MULTI-DOSE in 1 CARTON (70069-024-25) / 30 mL in 1 VIAL, MULTI-DOSE (70069-024-01) | June 8, 2018 |
| 50090-3541 | 50090-3541 | A-S Medication Solutions | — | September 7, 1982 |
| 87063-289 | 87063-289 | ASCLEMED USA INC. | — | July 15, 1975 |
| 87063-290 | 87063-290 | ASCLEMED USA INC. | — | July 15, 1975 |
| 80425-0261 | 80425-0261 | Advanced Rx Pharmacy of Tennessee, LLC | — | February 16, 2023 |
| 76420-555 | 76420-555 | Asclemed USA, Inc. | — | July 15, 1975 |
| 55154-5118 | 55154-5118 | Cardinal Health 107, LLC | — | September 7, 1982 |
| 72572-120 | 72572-120 | Civica, Inc. | — | November 13, 2019 |
| 72572-122 | 72572-122 | Civica, Inc. | — | November 13, 2019 |
| 55150-304 | 55150-304 | Eugia US LLC | — | June 5, 2020 |
| 55150-305 | 55150-305 | Eugia US LLC | — | June 7, 2019 |
| 68083-473 | 68083-473 | Gland Pharma Limited | — | August 4, 2021 |
| 68083-474 | 68083-474 | Gland Pharma Limited | — | August 4, 2021 |
| 68083-607 | 68083-607 | Gland Pharma Limited | — | September 25, 2023 |
| 51662-1297 | 51662-1297 | HF Acquisition Co LLC, DBA HealthFirst | — | July 21, 2019 |
| 51662-1343 | 51662-1343 | HF Acquisition Co LLC, DBA HealthFirst | — | December 22, 2018 |
| 51662-1541 | 51662-1541 | HF Acquisition Co LLC, DBA HealthFirst | — | May 20, 2022 |
| 51662-1660 | 51662-1660 | HF Acquisition Co LLC, DBA HealthFirst | — | July 15, 1975 |
| 0404-9805 | 0404-9805 | Henry Schein, Inc. | — | December 9, 2024 |
| 0641-0367 | 0641-0367 | Hikma Pharmaceuticals USA Inc. | — | September 7, 1982 |
| 0641-6145 | 0641-6145 | Hikma Pharmaceuticals USA Inc. | — | July 15, 1975 |
| 0641-6146 | 0641-6146 | Hikma Pharmaceuticals USA Inc. | — | July 15, 1975 |
| 71872-7091 | 71872-7091 | Medical Purchasing Solutions, LLC | — | September 7, 1982 |
| 71872-7164 | 71872-7164 | Medical Purchasing Solutions, LLC | — | July 15, 1975 |
| 71872-7171 | 71872-7171 | Medical Purchasing Solutions, LLC | — | July 15, 1975 |
| 71872-7239 | 71872-7239 | Medical Purchasing Solutions, LLC | — | June 7, 2019 |
| 70518-0532 | 70518-0532 | REMEDYREPACK INC. | — | May 17, 2017 |
| 70518-3724 | 70518-3724 | REMEDYREPACK INC. | — | April 25, 2023 |
| 70069-021 | 70069-021 | Somerset Therapeutics, LLC | — | April 19, 2018 |
| 70069-022 | 70069-022 | Somerset Therapeutics, LLC | — | June 8, 2018 |
| 70069-023 | 70069-023 | Somerset Therapeutics, LLC | — | June 8, 2018 |
| 70069-024 | 70069-024 | Somerset Therapeutics, LLC | — | June 8, 2018 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
| Enforcement | FDA | Recall records |
Generated September 25, 2026 · 13 sections on this page.